Duration of Ictal Hypoxemia is Associated With Potentially High-Risk Cardiac Arrhythmias in EpilepsyDecember 06, 2017
Duration of ictal/postictal hypoxemia may be associated with potentially high-risk cardiac arrhythmias during FBTCSs/GTCSs.
The drug is the first and only IV formulation of the antiepileptic carbamazepine.
The drug's pediatric exclusivity expires in March 2017.
Surgery had a significant impact on mortality even if seizures were not completely eliminated.
The Brain Sentinel device was as sensitive as vEEG review by an epileptologist for seizure detection.
Heart rate, arterial oxygenation, and electrodermal activity improved accuracy compared with heart rate alone.
Inhibiting the pathway upstream of mTOR at the level of PI3K signaling, a locus of significant molecular crosstalk in this pathway, restored the seizure-induced learning and memory deficits.
3D printing technology is used to create a porous drug that disintegrates rapidly with just a sip of liquid.
Treatment with in-MDZ reduced frequency of subsequent and generalized tonic-clonic seizure.
Neurology Advisor Articles
- McDonald Criteria Update: Further Distinction Between Relapsing-Remitting, Primary-Progressive MS
- Distinct Clinical Characteristics Associated With Subarachnoid Hemorrhage
- Increased Epilepsy Risk Identified in Multiple Sclerosis
- Magnesium Plus Environmental Enrichment Boosts Cognition, Memory in Alzheimer's Mouse Model
- Prognostic Significance of Weight Loss in Patients With Early Parkinsonism
- Coffee Consumption May Decrease Stroke Risk
- When and How to Approach Driving Cessation in Patients With Dementia
- NBT System Gets FDA Clearance for Depression Treatment
- Erenumab, Fremanezumab Reduce Migraine Frequency, Burden
- Some Antiepileptic Drugs Associated With Increased Risk for Toxic Epidermal Necrolysis
- Deep Brain Stimulation Improves Survival in Parkinson Disease
- Induced Hypertension Does Not Improve Outcomes in Subarachnoid Hemorrhage, Cerebral Ischemia
- Devices for Acute, Preventive Migraine Care Now Available
- Evolocumab FDA Approved for Stroke Prevention in Cardiovascular Disease
- Depression in Parkinson Disease Linked to Impaired White Matter Integrity